Literature DB >> 27862730

Disease course after clinically isolated syndrome in children versus adults: a prospective cohort study.

R M van der Vuurst de Vries1, E D van Pelt1, J Y Mescheriakova1, Y Y M Wong1, I A Ketelslegers1, T A M Siepman1, C E Catsman1, R F Neuteboom1, R Q Hintzen1.   

Abstract

BACKGROUND AND
PURPOSE: Clinically isolated syndrome (CIS) is a first demyelinating event of the central nervous system and can be a single event. After CIS, a chronic disease course with ongoing inflammation and relapses might occur, resulting in a diagnosis of multiple sclerosis (MS). As yet, there has been no prospective exploration of whether children and adults with CIS have the same disease course.
METHODS: Patients with CIS, whose age ranged from 1 to 50 years, were prospectively followed. We divided the patients into three different age groups, i.e. 1-10, 11-17 and 18-50 years old. Demographic data, disease course, time to MS diagnosis and annualized relapse rates (ARRs) were compared among these groups.
RESULTS: We included 383 patients with CIS, of whom 218 (56.9%) were diagnosed with MS. Children of between 11 and 17 years old had the highest rate of MS conversion (83.5% vs. 50.0% in the other age groups together, P < 0.01) and the shortest time to MS diagnosis [median time 2.6 months (interquartile range, 0.6-6.0) vs. 8.2 months (interquartile range, 1.9-28.2) in the other age groups together, P < 0.01). ARRs corrected for follow-up were higher in children of <18 years old than in adults of ≥18 years old with MS (mean ARR, 0.65 vs. 0.43, P < 0.01).
CONCLUSION: Children with CIS tend to have a more inflammatory disease course appearing from higher ARRs in all children and the highest rate of MS conversion in 11-17-year-old children. This supports early initiation of disease-modifying therapy in children, perhaps even at the first event in children at high risk for MS in line with clinical practice in adults.
© 2016 EAN.

Entities:  

Keywords:  adults; children; clinically isolated syndrome; multiple sclerosis

Mesh:

Year:  2016        PMID: 27862730     DOI: 10.1111/ene.13196

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  4 in total

1.  Real-world validation of the 2017 McDonald criteria for pediatric MS.

Authors:  Yu Yi M Wong; C Louk de Mol; Roos M van der Vuurst de Vries; E Daniëlle van Pelt; Immy A Ketelslegers; Coriene E Catsman-Berrevoets; Rinze F Neuteboom; Rogier Q Hintzen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-12-14

2.  Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.

Authors:  Arlette L Bruijstens; Katelijn M Blok; Joost Smolders; Beatrijs Ha Wokke; Rinze F Neuteboom
Journal:  Mult Scler       Date:  2020-05-14       Impact factor: 6.312

3.  T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes.

Authors:  Yu Yi M Wong; Roos M van der Vuurst de Vries; E Daniëlle van Pelt; Immy A Ketelslegers; Marie-José Melief; Annet F Wierenga; Coriene E Catsman-Berrevoets; Rinze F Neuteboom; Rogier Q Hintzen
Journal:  Mult Scler       Date:  2018-07-18       Impact factor: 6.312

4.  High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.

Authors:  Roos M van der Vuurst de Vries; Yu Yi M Wong; Julia Y Mescheriakova; E Daniëlle van Pelt; Tessel F Runia; Naghmeh Jafari; Theodora Am Siepman; Marie-José Melief; Annet F Wierenga-Wolf; Marvin M van Luijn; Johnny P Samijn; Rinze F Neuteboom; Rogier Q Hintzen
Journal:  Mult Scler       Date:  2018-05-18       Impact factor: 6.312

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.